High-dose radiation associated with improved survival in IDH-wildtype lowgrade glioma

作     者：Shuai Liu Yanwei Liu Guanzhang Li Jin Feng Li Chen Xiaoguang Qiu Liu Shuai;Liu Yanwei;Li Guanzhang;Feng Jin;Chen Li;Qiu Xiaoguang

作者机构：Department of Radiation OncologyBeijing Tiantan HospitalCapital Medical UniversityBeijing 100070China Department of Molecular NeuropathologyBeijing Neurosurgical InstituteCapital Medical UniversityBeijing 100070China 

出 版 物：《Chinese Neurosurgical Journal》 (中华神经外科杂志（英文）)

年 卷 期：2021年第7卷第2期

页      面：126-130页

核心收录：

学科分类：1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100214[医学-肿瘤学] 10[医学] 1009[医学-特种医学] 

基　　金：This work was supported by The National Natural Science Foundation of China(Grant Numbers:82001778) The Capital Medical Development Research Fund(Grant Numbers:2020-2-1072). 

主　　题：Radiation dose IDH-wildtype Low-grade glioma Survival 

摘      要：Background:As molecular advances have deepened the knowledge on low-grade glioma(LGG),we investigated the effect of higher radiation dose on the survival of IDH-wildtype(IDHwt)LGG.Methods:In the current study,52 IDHwt LGG patients who received radiotherapy were enrolled from the Chinese Glioma Genome Atlas dataset.Radiation doses54 Gy were defined as high-dose,whereas doses≤54 Gy were defined as low-dose.We performed univariate and multivariate survival analyses to examine the prognostic role of high-dose radiotherapy.Results:In total,the radiation dose ranged from 48.6 Gy to 61.2 Gy,with a median of 55.8 Gy,and 31 patients were grouped into high-dose radiation.Univariate survival analysis indicated that high-dose radiotherapy(p=0.015),tumors located in the frontal lobe(p=0.009),and pathology of astrocytoma(p=0.037)were significantly prognostic factors for overall survival.In multivariate survival analysis,high-dose radiotherapy(p=0.028)and tumors located in the frontal lobe(p=0.016)were independently associated with better overall survival.Conclusions:In conclusion,high-dose radiotherapy independently improved the survival of IDHwt LGG.This can guide treatments for glioma with known molecular characteristics.